Issue: June 2020
June 17, 2020
1 min read
Save

ODYSSEY HoFH

Issue: June 2020
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LDL reduction with alirocumab (Praluent, Sanofi/Regeneron) every 2 weeks vs. placebo in patients with homozygous familial hypercholesterolemia.